Device Trial Radar · NCT06637293
Deployment and Evaluation of Artificial Intelligence Software for Electrocardiogram Analysis and Management in Primary Care
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
2,000
Planned (sponsor's estimate)
Start
Oct 2, 2025
Primary completion
Jan 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Montreal Heart InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 15, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Diagnostic
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The DAISEA-ECG project aims to improve the diagnosis of heart diseases in primary care through the DeepECG platform, which combines ECG-AI and ECHONeXT algorithms. This study uses a stepped wedge design, where each Family Medicine Group acts as its own control. The FMGs will gradually transition from the control period (without AI recommendations) to the intervention period (with AI recommendations activated) in a randomized sequence. The primary objective is to compare the sensitivity of family physicians in detecting cardiac pathologies, with and without the assistance of the DeepECG platform. Sensitivity is defined as the proportion of patients correctly referred to cardiology or for transthoracic echocardiography (TTE) among those who indeed required cardiovascular evaluation, as confirmed by an independent adjudication committee.
Conditions
- Primary Care Provider
- Structural Heart Disease
Interventions
DeepECG plateform diagnosis & recommendationsDevice
EchoNeXT\& ECG-AI algorithm
Primary outcomes
What the sponsor says the trial is designed to measure.
- sensitivity of cardiology referralsTime frame: 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Montreal Heart Institute
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.